{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-018128","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2026-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.654938+00:00","generated_at":"2026-05-16T01:24:06.920718+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fennec real-world data show PEDMARK safe in adults with head & neck cancers, no disruption to cisplatin therapy","bullets":["Data from retrospective review of 15 adult HNC patients presented at 2026 MHNCS symposium (Feb 19-21).","PEDMARK given ≥6 hours after cisplatin was feasible and well tolerated; no grade 3/4 toxicities observed.","Majority of high-risk patients had no measurable hearing loss during or after treatment despite baseline impairment.","No disruption to curative-intent cisplatin-based treatment delivery was noted in the study."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-018128","json":"https://secwatch.observer/filing/0001104659-26-018128.json","markdown":"https://secwatch.observer/filing/0001104659-26-018128.md","text":"https://secwatch.observer/filing/0001104659-26-018128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926018128/0001104659-26-018128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926018128/fencf-20260220x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:24:06.920718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}